Syncona

Overview

Compare with another stock.

• TickerBACT on London Stock Exchange¹
• HeadquartersSaint Peter Port¹
• Websitewww.synconaltd.com
• Legal formcompany limited by shares³
• LEI213800X8MBI5VQITLW60³
• StatusActive³
• LEI statusIssued and current³
• Registered addressFRANCES HOUSE, P O BOX 273, GY1 3RD St Peter Port, Guernsey³
• Registered withGuernsey Registry, 55514³

See how the biggest companies compare on our leaderboards

Syncona (LSE: SYNC) is a large British closed-ended investment trust dedicated to life science investments. Co-founded as Syncona Partners in 2012 by former CEO Martin Murphy and the Wellcome Trust, before merging with the Battle Against Cancer Investment Trust ('BACIT') in December 2016 and listing publicly, the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. Its Chair is Melanie Gee.²

Corporate structure

Syncona sits at the top of its group. 5 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0). Each entity in the chart links to its source.

What it owns

What Syncona reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Stakes and holdings (Wikidata)

• Autolus Therapeutics 30.6%

Things Wikidata records the company as owning, with the share when stated.¹

Subsidiaries and ownership

Owners

• Wellcome Trust 28%

Also owns

• Autolus Therapeutics 30.6%

From Wikidata.¹

Timeline

1. Aug 14, 2012Founded Founded¹

Links

• Websitewww.synconaltd.com¹
• WikipediaSyncona
• WikidataQ29026384